SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

SIGA Technologies, Inc.NASDAQ: SIGA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $752.97K fell 16.5% year over year, behind the +3.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +27.4% a year.

Context

  • Stock-based compensation amounted to 3.9% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -16.5% toward the trailing-twelve-month pace of +3.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$752.97K-2.5% QoQ
Last fiscal yearDec 2025
$3.68M+1.2% YoY
LTMMar 2026
$3.53M+3.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.5%——
1 year+1.2%——
3-year CAGR+27.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.68M USD
Year-over-year change
+1.2%
4-year CAGR
+30.6%

Stock-Based Compensation vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.6% is the 6th highest of 10, against a peer median of +17.3%.
  • Stock-based compensation amounts to 3.8% of revenue for SIGA, versus a peer median of 3.5%.
SIGA Competitors
Stock-Based Compensation for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$16.6M USD+22.1%-28.9%2.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$13.57M USD+17.6%+26.6%2.6%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M USD-40.1%——
SNDLSNDL Inc.LTM Mar 2026CA$13.13M CAD-20.8%+12.9%1.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M USD+21.4%+0.9%4.3%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$9.91M USD-11.7%-13.4%2.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$9.12M USD+17.3%-21.7%25.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$8.36M USD+17.6%+20.3%16.6%
DRIODarioHealth Corp.LTM Mar 2026$5.51M USD-51.1%-18.0%26.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$3.53M USD+3.6%+27.4%3.8%
Peer median (excluding SIGA) —+17.3%-6.3%3.5%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income69.45M33.9M68.07M59.21M23.28M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
Deferred Income Tax121.45K(3.83M)(4.8M)193.42K6.43M
Stock-Based Compensation1.27M1.78M2.05M3.64M3.68M
Change in Working Capital(60.37M)9.44M28.36M(4.69M)8.26M
Accounts Receivables(80.31M)38.24M24.28M(35.18K)17.9M
Inventory136.37K(19.96M)(25.52M)15.34M(846.31K)
Accounts Payables1.47M2.07M2M(5.74M)(578.64K)
Other Working Capital18.34M(10.91M)27.61M(14.26M)(8.22M)
Other Non-Cash Items501K(199.19K)579.24K(10.13M)1.26M
Operating Cash Flow11.49M41.61M94.8M48.76M43.47M
Capital Expenditures(50.62K)0(21.69K)(42.45K)(355.01K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(50.62K)0(21.69K)(42.45K)(355.01K)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased(26.02M)(13.01M)(11.07M)(799.9K)0
Dividends Paid0(32.94M)(32.14M)(42.67M)(43.12M)
Other Financing Activities(173.92K)(12.53K)(214.79K)0(433.76K)
Financing Cash Flow(26.2M)(45.96M)(43.42M)(43.46M)(43.55M)
Effect of Forex Changes00000
Net Change in Cash(14.75M)(4.35M)51.36M5.25M(433.85K)
Free Cash Flow11.44M41.61M94.78M48.72M43.12M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.